Biotech Values

[biotech_researcher]

I believe Rachel McMinn has again lost course. She was way late in coverage of Ariad a few years ago. Then, last September I believe, she raises Ariad from $25 to $30, including a value of $3 to $4 for AP26113. Recently, she has increased her price target from $2 to $3, giving Zero value for '113. She is absolutely clueless, imo, and is condescending on the CC with Ariad.